ARTICLE | Clinical News
Aquila grants license to Neurolab
January 18, 2000 8:00 AM UTC
AQLA granted an exclusive, worldwide license to Neurolab (Bermuda) to use Stimulon adjuvant QS-21 with an undisclosed antigen for Alzheimer's disease. AQLA received a license payment and could receive...